Phase 1/2 Trial of the Novel Hsp90 Inhibitor, IPI-504, in Patients with Relapsed and/or Refractory Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Stratified by EGFR Mutation Status


*Massachusetts General Hospital Cancer Center, Boston, MA USA; **Dana-Farber Cancer Institute, Boston, MA USA; Infinity Pharmaceuticals, Cambridge, MA USA

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics • San Francisco, CA • October 2007

Abstract

Introduction: Hsp90 has emerged as a promising molecular target in the treatment of cancer. Recent studies have demonstrated the involvement of Hsp90 in many different cancers. The biologic and anti-neoplastic effects of IPI-504 have been demonstrated in multiple human xenograft and murine models of cancer in vivo and in vitro. IPI-504 is a selective Hsp90 inhibitor that selectively and irreversibly inhibits the Hsp90 chaperone complex in a pH and enzyme-mediated dynamic redox equilibrium. (Ge; Demetri 2006) The recommended dose and schedule of 400 mg/m² was determined in two Phase 1 studies conducted in patients with metastatic, imatinib and sunitinib-resistant GIST. (Demetri 2007) IPI-504 is being studied in several different clinical trials. Data recently presented has shown that the compound is active in a Phase I clinical trial in patients with metastatic, imatinib and sunitinib-resistant GIST. (Demetri 2007)

MATERIALS AND METHODS

Dose and Schedule Amendment for Phase 2

- Dose and schedule amendment for phase 2 was determined in two Phase 1 studies conducted in patients with metastatic, imatinib and sunitinib-resistant GIST. (Demetri 2007)
- IPI-504 is being studied in several different clinical trials. Data recently presented has shown that the compound is active in a Phase I clinical trial in patients with metastatic, imatinib and sunitinib-resistant GIST. (Demetri 2007)

RESULTS

- Dose and schedule amendment for Phase 2

Conclusions

- The primary objective of the Phase 1 portion of the study was to be completed with a schedule of twice weekly dose administration for 2 weeks followed by 10 days off
- Dose and schedule amendment for Phase 2
- Duration of Treatment

Acknowledgements

- We are deeply grateful to

References